Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors
J. Clin. Invest. Philipp Beckhove, et al. 114:67 doi:10.1172/JCI20278 [Go to this article.]

Figure 5
Perforin expression by autologous memory T cells and rejection of xenografted cancer specimens in NOD/SCID mice after ADI. (A) Perforin expression (with isotype control depicted in gray) in CD8⁺CD45RA^– CM and EM T cells 6 days after coculture with DCs pulsed with autologous Tu-L. Results from one representative experiment of four are shown. (B) Accumulative data for perforin expression by memory T cells from BM of four patients stimulated with DCs pulsed with Tu-L (black bars) or left unstimulated (white bars). *P < 0.01; **P < 0.05. (C) Tumor volumes were measured before therapy (white bars) and 4 weeks after therapy (black bars). Means ± SD of three independent experiments. Mice were left untreated (control) or were injected with memory T cells activated by DCs pulsed with Tu-L [CD45RA^–; RA^–(Tu-L)] or PB-L [CD45RA^–; RA^–(PB-L)], or were treated with naive T cells activated by DCs pulsed with Tu-L [CD45RA⁺; RA⁺(Tu-L)]. *P = 0.03 for the experimental (CD45RA^–, TU-L) versus each control group. (D–G) Tumors from treated (D and F) or untreated (E and G) animals were stained for perforin (D and E) and apoptotic cells (F and G) 9 days after therapy. Original magnification, ×200. (D). Staining from one representative experiment of three is shown. (H) Accumulative data of perforin⁺ and apoptotic cells in treated (black bars) and untreated (gray bars) tumors. *P < 0.01, difference between numbers of perforin⁺ TILs in experimental and control mice; **P < 0.05, difference between apoptotic cell numbers in experimental and control animals.